- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02837445
Moderato System: A Double-Blind Randomized Trial Ver 1.1
Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial
The purpose of this double blind randomized study is the evaluation of the safety and efficacy of the Moderato System.
The Moderato implantable pulse generator is indicated for patients who have hypertension and also require a dual chamber pacemaker in order to reduce their blood pressure.
The primary objectives of this study are to provide evidence of safety and clinical efficacy of the anti-hypertensive effects of the Moderato System. This will be accomplished by evaluating changes in blood pressure in an active treatment vs. a control patient population for a period of 6 months.
The device will be considered to have a clinical effectiveness with regard to its anti-hypertension functions if there is a statistically significant and clinically meaningful reduction in mean 24-hour ambulatory systolic blood pressure in the treatment group compared to the control group.
Study Overview
Status
Intervention / Treatment
Detailed Description
Protocol CS-03 Ver 1.1 (NCT02837445) was amended at the advice of the Scientific Advisory to protocol CS-03 Version 3.0 with more stringent hypertension inclusion criteria and different observation intervals for efficacy and safety.
In CS-03 Version 3.0 the time of the primary efficacy endpoint was reduced from 6 months to 3 months post randomization which was deemed a suitable interval for the chronic effect, whereas for the safety endpoint, the period was lengthened from 6 month to 12 months post randomization to better monitor potential risks of the treatment on cardiac function (Blinding period was increased from 6 to 12 months). Protocols were thus split in order to allow better clarification to the difference in the time to the primary endpoints for efficacy and safety between the two CIP versions and simplify data analysis.
Protocol Ver 3.0 prescribes data analysis of all patients randomized under version 1.1 to be performed once they complete the 6 months follow-up as set in protocol version 1.1 (NCT0283744). It is expected that ~40 patients will be randomized according to protocol version 1.1 prior to the enrollment of patients according to protocol version 3.0. The results will be considered as interim analysis.
The recruitment for the protocol version 1.1 is now completed. Total of 47 patients were randomized according to protocol version 1.1 and all patients completed the follow-up period for the primary endpoint.
Patients are currently being followed up for the study "extension period".
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Linz, Austria, 4020
- Krankenhaus der Elisabethinen
-
Vienna, Austria, 1090
- Medical University Vienna
-
-
-
-
-
Brussels, Belgium, 1090
- UZ Brussel - Heart Rhythm Management Center
-
-
-
-
-
Prague, Czechia, 15030
- Na Homolce Hospital
-
-
-
-
-
Budapest, Hungary, 1122
- Semmelweis University Heart and Vascular Center
-
-
-
-
-
Riga, Latvia, 1002
- P. Stradins Clinical University Hospital
-
-
-
-
-
Vilnius, Lithuania, 08661
- Vilnius University Hospital Santariskiu Klinikos
-
-
-
-
-
Gdańsk, Poland, 80-952
- Medical University of Gdansk
-
Poznań, Poland, 61-848
- Szpital Kliniczny Przemiemienia Panskiego
-
Szczecin, Poland, 70-111
- Pomeranian Medical University Hospital no. 2
-
Warsaw, Poland, 02-097
- Samodzielnym Publicznym Centralnym Szpitalem Klinicznym
-
Zabrze, Poland, 41-800
- Silesian Center for Heart Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject requires an implant or replacement a of dual chamber pacemaker
- Stable (at least one month) hypertension treatment with at least 1 anti-hypertensive drug, which is anticipated to be maintained for 7 months.
- Average day time (7AM-10PM) ambulatory systolic blood pressure ≥ 130 mmHg and office blood pressure ≥140 mmHg.
- Subject lives in the proximity of the study center, which permits compliance with study visits for at least 7 months.
Exclusion Criteria:
- Known secondary cause of HTN.
- Average ambulatory or office systolic BP > 195 mmHg.
- Permanent atrial fibrillation.
- History of significant paroxysmal atrial fibrillation/flutter burden (defined as >25% of beats).
- Cardiac ejection fraction <50%.
- Symptoms of heart failure, NYHA Class II or greater.
- Hypertrophic cardiomyopathy, restrictive cardiomyopathy or inter-ventricular septal thickness ≥ 15 mm.
- Subject is on dialysis.
- Subject has an estimated Glomerular Filtration Rate < 30 ml/min/1.73 m²
- Prior neurological events (stroke or TIA) within the past year or events at a prior time that has resulted in residual neurologic deficit.
- Carotid artery disease.
- Known autonomic dysfunction.
- History of clinically significant untreated ventricular tachyarrhythmia or has experienced sudden death.
- Previous active device-based treatment for HTN.
- Existing implant, other than a pacemaker that needs replacing.
- Subject is or has the possibility of becoming pregnant and is unwilling of contraception during the study.
- Subject is unwilling or cannot provide Informed Consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment
Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
|
Eligible patients randomized after optimization phase to PHC ON for 6 months.
Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
|
Placebo Comparator: Control
Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months.
Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
|
Eligible patients randomized after optimization phase to PHC OFF for 6 months.
Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of composite of major cardiac events
Time Frame: 6 months post Randomization
|
including heart failure, clinically significant arrhythmias eg, persistent or increased atrial fibrillation, serious ventricular arrhythmias, myocardial infarction, stroke, heart failure, renal failure and/or related safety events that result in death
|
6 months post Randomization
|
Change in average 24 hour systolic ambulatory blood pressure
Time Frame: Week 3 pre Randomization and 6 months post Randomization
|
Week 3 pre Randomization and 6 months post Randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Karl-Heinz Kuck, Prof. MD, Asklepios Klinik St. Georg
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS-03 Ver 1.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bradycardia
-
Augusta UniversityCompletedFetal BradycardiaUnited States
-
University of Maryland, BaltimoreCompleted
-
University of Sao Paulo General HospitalCompletedFetal Bradycardia | Hypertonic Uterine | CatecholaminesBrazil
-
Chun Chieh WangEnrolling by invitation
-
University of ExeterRoyal Devon and Exeter NHS Foundation TrustCompletedSVT | Vagal BradycardiaUnited Kingdom
-
Abbott Medical DevicesCompletedStandard Bradycardia Pacing IndicationFrance, Germany, Italy, Japan
-
Medical University of GdanskCompletedBradycardia During Pulling of EyeballPoland
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
South Western Ambulance Service NHS Foundation...Royal Devon and Exeter NHS Foundation Trust; Academic Health Science CentresCompletedEmergencies | SVT | Vagal BradycardiaUnited Kingdom
-
Unyime ItukRecruitingFetal Heart Rate or Rhythm Abnormality Affecting Fetus | Fetal Bradycardia Complicating Labor and Delivery | Fetal Bradycardia During LaborUnited States
Clinical Trials on PHC ON
-
BackBeat Medical IncActive, not recruiting
-
University Hospital HeidelbergDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyWithdrawn
-
University Hospital HeidelbergNot yet recruitingMetastatic Colorectal CancerGermany
-
Masa BosnjakUniversity of Ljubljana; Institute of Oncology LjubljanaCompleted
-
Institute of Oncology LjubljanaUniversity Medical Centre LjubljanaCompleted
-
Sinocelltech Ltd.Not yet recruiting
-
University of Sao PauloCompleted
-
University of Sao PauloCompletedDuchenne Muscular DystrophyBrazil
-
Institute of Oncology LjubljanaUniversity Medical Centre Ljubljana; University of Ljubljana; University Medical...Completed
-
Universidade Federal de PernambucoUnknown